Concepedia

Publication | Open Access

Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study

DOIFull Paper Access

22

Citations

27

References

2017

Year

Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg,
Allergology International

Abstract

This subgroup analysis demonstrated that omalizumab is a well-tolerated, beneficial option for treatment of CSU in H<sub>1</sub>AH-refractory Japanese patients.

References

YearCitations

Page 1